Clinical trials of angiogenesis inhibitors for advanced breast cancer (metastatic) in second line therapy

TrialResults-center www.trialresultscenter.org

1 combination with CT (without taxanes)

Trial	Treatments	Patients	Trials design and methods
bevacizumab + capecitabine vs capecitabine			
AVF2119g (Miller) cape , 2005 n=232/230 follow-up:	capecitabine + bevacizumab 15 mg/kg iv every 3 weeks versus capecitabine (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks	patients with metastatic breast cancer previously treated with an anthracycline and a taxane	Parallel groups open US
bevacizumav + CT vs CT alone			
RIBBON-2 (Brufsky) , 2009 n=NA follow-up:	addition of BV to chemotherapies used as second-line treatment for MBC versus chemo+placebo	second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer	Parallel groups open 19 countries

References

AVF2119g (Miller) cape, 2005:

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9 [15681523] 10.1200/JCO.2005.05.098

RIBBON-2 (Brufsky), 2009:

Brufsky A, Rivera RR, Hurvitz SA, et al: Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for secondline treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC) J Clin Oncol 28: 119s, 2010 (abstr 1021)

Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-93 [21990397]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.